Concepedia

Erika Hitre

EH

38

Publications

11.4K

Citations

28

H-Index

2004

Active since

Affiliations

National Institute of Oncology(Current)

Dana-Farber Cancer Institute

The University of Texas MD Anderson Cancer Center

The University of Sydney

Semmelweis University

Erika Hitre is an author at National Institute of Oncology specializing in oncology, medicine, and cancer therapeutics.

Top concepts

Publications per year

2004–2024

38

Publications

38

Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer

Eric Van Cutsem, Claus-Henning Köhne, Erika Hitre et al. · New England Journal of Medicine · 2009 · 3.8K citations · Full text

First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial

Yelena Y. Janjigian, Kohei Shitara, Markus Moehler et al. · The Lancet · 2021 · 2.7K citations · Full text

, , +7

Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes in a Phase III Randomized Adjuvant Breast Cancer Trial in Node-Positive Breast Cancer Comparing the Addition of Docetaxel to Doxorubicin With Doxorubicin-Based Chemotherapy: BIG 02-98

Sherene Loi, Nicolas Sirtaine, Fanny Piette et al. · Journal of Clinical Oncology · 2013 · 1.6K citations

Trastuzumab-Associated Cardiac Adverse Effects in the Herceptin Adjuvant Trial

Thomas Suter, Marion Procter, Dirk J. van Veldhuisen et al. · Journal of Clinical Oncology · 2007 · 563 citations · Full text

Goserelin for Ovarian Protection during Breast-Cancer Adjuvant Chemotherapy

Halle C. F. Moore, Joseph M. Unger, Kelly‐Anne Phillips et al. · New England Journal of Medicine · 2015 · 530 citations · Full text

Rows per page

1–5 of 38